CYP2D6 IM/PMs have been associated with reduced endoxifen plasma concentration [102], although the evidence relating CYP2D6 to clinical outcomes indicative of reduced tamoxifen efficacy, such as breast cancer recurrence and mortality, are inconsistent [101]. The gene discussed is CYP2D6; the disease is breast carcinoma.